MEDNAX (NYSE:MD) had its target price increased by JPMorgan Chase & Co. from $46.00 to $55.00 in a report published on Monday. JPMorgan Chase & Co. currently has a neutral rating on the stock.

Other equities analysts have also recently issued research reports about the company. KeyCorp set a $51.00 price target on MEDNAX and gave the stock a buy rating in a research note on Wednesday, November 1st. Stephens set a $62.00 price target on MEDNAX and gave the stock a buy rating in a research note on Thursday, February 8th. Zacks Investment Research raised MEDNAX from a hold rating to a buy rating and set a $60.00 price target on the stock in a research note on Tuesday, January 23rd. SunTrust Banks set a $55.00 price target on MEDNAX and gave the stock a hold rating in a research note on Thursday, December 21st. Finally, Jefferies Group restated a hold rating and set a $44.00 price objective on shares of MEDNAX in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $54.92.

MEDNAX (MD) opened at $54.76 on Monday. The firm has a market capitalization of $5,130.00, a PE ratio of 15.92, a P/E/G ratio of 1.48 and a beta of 0.31. MEDNAX has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.43 and a quick ratio of 1.37.

MEDNAX (NYSE:MD) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.83 by $0.04. The firm had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. MEDNAX’s revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business posted $1.00 EPS. analysts expect that MEDNAX will post 3.67 earnings per share for the current fiscal year.

In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares in the company, valued at approximately $1,834,649.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Thompson Siegel & Walmsley LLC lifted its holdings in shares of MEDNAX by 19.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after buying an additional 428,184 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of MEDNAX by 4.8% during the 3rd quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock valued at $100,198,000 after buying an additional 106,883 shares during the last quarter. Earnest Partners LLC lifted its holdings in shares of MEDNAX by 48.1% during the 4th quarter. Earnest Partners LLC now owns 2,212,691 shares of the company’s stock valued at $118,246,000 after buying an additional 718,317 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its holdings in shares of MEDNAX by 6.8% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,515,288 shares of the company’s stock valued at $80,977,000 after buying an additional 96,005 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of MEDNAX by 25.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,424,574 shares of the company’s stock valued at $61,428,000 after buying an additional 293,011 shares during the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://theolympiareport.com/2018/02/15/mednax-md-price-target-increased-to-55-00-by-analysts-at-jpmorgan-chase-co.html.

About MEDNAX

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.